A Review of Immunotherapy in Non-Small-Cell Lung Cancer.

Curr Oncol · 2024 · PMC11203112 · PMID 38920741

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Furthermore, in one of the trials included in this analysis, among patients with baseline brain metastases, there was a nonsignificant trend toward reduction in the risk of developing new CNS lesions with atezolizumab compared with docetaxel (hazard ratio [HR] 0.42, CI [0.15–1.18]).

also in 5,406 other papers

a positive trendno p-value reported

There was also a positive trend in the PDL-1 < 1 subgroup [ 20 ].

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.